Venus Remedies secures firstiInternational market authorization for Sugammadex from the Philippines
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025
The PIPE offering consists of 36,190,476 units
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
Subscribe To Our Newsletter & Stay Updated